Aurora kinase inhibitors: Progress towards the clinic

Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in Aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81:95–105 Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015 Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842–854 Chen HL, Tang CJ, Chen CY, Tang TK (2005) Overexpression of an Aurora-C kinase-deficient mutant disrupts the Aurora-B/INCENP complex and induces polyploidy. J Biomed Sci 12:297–310 Marumoto T, Honda S, Hara T et al (2004) Aurora-A kinase maintains the fidelity of late and early mitotic events in HeLa cells. J Bio Chem 278:51786–1795 Portier N, Audhya A, Maddox PS, Green RA, Dammermann A, Desai A, Oegema A (2007) A microtubule-independent role for centrosomes and Aurora A in nuclear envelope breakdown. Dev Cell 12:515–529 Adams RR, Maiato H, Earnshaw WC, Carmena M (2001) Essential roles of Drosophila inner centromere protein (INCENP) and Aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Biol Chem 15:865–880 Knowlton AL, Lan W, Stukenberg P (2006) Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol 16:1705–1710 Goto H, Yasui Y, Nigg EA, Inagaki M (2002) Aurora B phosphorylates histone H3 at serine 28 with regard to the mitotic chromosome condensation. Genes Cells 7:11–17 Li X, Sakashita G, Matsuzaki H, Sugimoto K, Kimura K, Hanaoka F, Taniguchi H et al (2004) Direct association with inner centromere protein (INCENP) activates the novel chromosomal protein, Aurora-C. J Biol Chem 279:47201–47211 Yan X, Cao L, Li Q, Wu Y, Zhang H, Saiyin H, Liu X et al (2005) Aurora C is directly associated with survivin and is required for cytokinesis. Genes Cells 10:617–626 Marumoto T, Zhang D, Saya H (2005) Aurora-A-a guardian of poles. Nat Rev Cancer 5:42–50 Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14:2195–2200 Reichardt W, Jung V, Brunner C, Klien A, Wemmert S, Romeike BF, Zang KD, Urbschat S (2003) The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep 10:1275–1279 Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkely BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189–193 Tchatchou S, Wirtenberger M, Hemminki K, Sutter C, Meindl A, Wappenschmidt B, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Burwinkel B (2007) Aurora kinases A and B and familial breast cancer risk. Cancer Lett 247:66–72 Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160–1162 Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalleti-Cernia D et al (2004) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928–935 Zeng WF, Navaratne K, Prayson RA, Weil RJ (2007) Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 60:218–221 Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ (2004) Aurora-A abrogation of p53 DNA binding and transactivation activity by serine 215. J Biol Chem 279:52175–52182 Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA et al (2009) Fragment based discovery of the pyra-4-yl-urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 52:379–388 Mortlock AA, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson RW, Green S (2005) Progress in the development of selective inhibitors of aurora kinases. Curr Top Med Chem 5:199–213 Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH (2006) Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure assisted, fragment-based approach. Mol Cancer Ther 5:1764–1773 Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA (2008) Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg Med Chem Lett 18:3978–3981 Fu DH, Jiang W, Zheng JT, Zhao GY, Li Y, Yi H, Li ZR et al (2008) Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol Cancer Ther 7:2386–2393 Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagam WM et al (2008) Discovery of potent and selective aurora kinase inhibitor. Biorg Med Chem Lett 18:4880–4884 Fancelli D, Berta D, Bindi S, Cameron A, Cappella P, Carpinelli P, Catana C et al (2005) Potent and selective Aurora inhibitors identified by a novel scaffold for protein kinase inhibition. J Med Chem 48:3080–3084 Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S et al (2006) 1, 4, 5, 6-tetrahydropyrrolo [3, 4-c] pyrozoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49:7247–7251 Aliagas-Martin H, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang OW et al (2009) A class of 2,4-bisanilinopyrimidine Aurora A inhibitor with unusually high selectivity against Aurora B. J Med Chem 52:3300–3307 Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Lai Z (2008) Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2. Protein Sci 17:1791–1797 De Lano WL (2002) The PyMOL molecular graphic system. De Lano Scientific LLC, San Carlos Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A et al (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158–3168 Paquette R, Shah N, Sawyers C, Martinelli G, Nicoll J, Chalukya M, Locatelli G, Capolongo L, Moll J, Comis S, Laffranchi B (2008) PHA-739358: a pan-Aurora kinase inhibitor. Haematol Meet Rep 2:92–93 Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA et al (2009) A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 15:6694–6701 Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L et al (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67:7987–7990 Wang S, Midgley CA, Scaerou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G et al (2010) Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora kinase inhibitors. J Med Chem 53:4367–4378 Griffiths G, Scaerou F, Sorrell D, Duckmanton A, Tosh C, Lewis S, Midgley C et al (2008) Anti-tumor activity of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2. AACR Annual Meeting; 12–16 April 2008, San Diego, CA, USA, Abstract 651 Hajduch M, Vydra D, Dzubak P, Stuart I, Zheleva D (2008) In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. AACR Annual Meeting; 12–16 April 2008, San Diego, CA, USA, Abstract 5645 Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO et al (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dose flexibility in vivo. Cancer Chemother Pharmacol 65:707–717 Robert F, Hurwitz H, Verschraegen CF, Verschraegen R, Advani R, Berman C, Taverna P, Evanchik M (2009) Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. ASCO Annual Meeting; 29 May-2 June 2009, Orlando, FL, USA, Abstract 14642 Bebbington D, Binch H, Charreir JD, Everitt S, Fraysee D, Golec J, Kay D et al (2009) The discovery of potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 19:3586–3592 Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262–267 Cheetam GM, Charlton PA, Golec JM, Pollard JR (2007) Structural basis for potent inhibition of the Aurora Kinases and a T135I multi-drug resistant form of Abl kinase by VX-680. Cancer Lett 251:323–329 Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M et al (2010) Activity of multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemia cells. Blood 116:2089–2095 Lyons J, Curry J, Reule M et al (2008) Biomarker identification of AT9283: a multitargeted kinase inhibitor with Aurora A and Aurora B activities from pre-clinical models to clinical trials. AACR centennial conference; 20–23 July 2008, California, USA Foran JM, Ravandi F, O’Brien SM, Borthakur G, Rios M, Boone J, Worrell K et al (2008) A phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor in patients with refractory leukemia. ASCO Annual Meeting; 30 May-3 June 2008, Chicago, IL,USA, Abstract 2518 Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V et al (2009) A phase I study of AT9283, an aurora kinase inhibitor in patients with refractory solid tumours, ASCO Annual Meeting; 29 May-2 June 2009,Orlando, FL,USA, Abstract 2566 McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, Franci C et al (2010) Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 136:99–113 Renshaw JS, Patnaik A, Gordon M, Beerman M, Fischer D, Gianella-Borradori A, Lin C, Mendelson D (2007) A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. ASCO Annual Meeting; 30 May–3 June 2007, Chicago, IL, USA, Abstract 14130 Sonet A, Graux C, Maertens J et al (2008) Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of aurora and other kinases, administered orally in patients with advanced hematological malignancies. Blood (ASH Annual Meeting) 2008:112 Bhattacharya S, Wishka D, Luzzio M, Arcari J, Bernardo V, Briere D, Boyden T et al (2008) SAR and chemistry of Aurora kinase inhibitors: discovery of PF-3814735, an oral clinical candidate. AACR Annual Meeting; 12–16 April 2008, San Diego, CA, USA Jani JP, Arcari J, Bernardo V (2010) PF-03814735, an orally bioavailable small molecule Aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 9:883–894 Schoffski P, Jone SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P et al (2011) Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 47:2256–2264 Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH et al (2010) Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 53:3973–4001 Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, Newlander K et al (2009) Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time. Biochem J 13:259–265 Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K et al (2009) GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor in tissue culture cells and human tumor xenografts models. Mol Cancer Ther 8:1808–1817 Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S et al (2010) Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 70:9846–9854 Sells T, Ecsedy J, Stroud S et al (2008) MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. AACR Annual Meeting; 12-16 April 2008, San Francisco, CA, USA, Abstract 237 Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15:2057–2070 Gorgun G, Calabrese E, Hideshima E, Ecsedy J, Perrone G, Mani M, Ikeda H et al (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115:5202–5213 Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST et al (2010) Initial testing of Aurora A inhibitor MLN8237 by the pediatric preclinical testing program. Pediatr Blood Cancer 55:26–34 Infante J, Dees EC, Cohen RB (2008) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. Eur J Cancer Suppl 6:90–91, Abstract 280 Fletcher GC, Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, Sidor CF, Bray MR (2010) ENMD-2076 is an orally-active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 10:126–137 Wang X, Sinn AL, Pollok A, Sandusky G, Zhang S, Chen L, Liang J et al (2010) Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 150:313–325 Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hassebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG (2010) Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase Inhibitor, against primary and cell line–derived human colorectal cancer xenograft models. Clin Cancer Res 16:2989–2998 Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya AA et al (2011) Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 17:849–860 Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T et al (2010) MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9:157–166 Minton SE, LoRusso P, Lockhart AC et al (2010) A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 28;15s suppl:abstr e13026 Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N et al (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Neoplasia 110:2034–2040 Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N et al (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50:2213–2224 Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR et al (2007) AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682–3688 Schellens JH, Boss D, Witteveen PO, Zandvliet A, Beijnen JH, Voogel-Fuchs M, Morris C, Wilson D, Voest EE (2006) Phase I and pharmacological study of the novel Aurora kinase inhibitor AZD1152. J Clin Oncol 24:3008 (suppl) Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G et al (2011) Phase I/II study to assess safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118:6030–6036 Boss DS, Witteveen PO, Van der sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH (2010) Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 22:431–437 Gurtler U, Tontsch-Grunt U, Jarvis M, Zahn SK, Boehmelt G, Quant J, Adolf GR et al (2010) Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol 28;suppl:abstr e13632 Mross KB, Scheulen ME, Frost A, Scharr D, Richly H, Nokay B, Lee K et al (2010) A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 28; 15s suppl:abstr 3011 Scheulen ME, Mross KB, Richly H, Nokay B, Frost A, Lee K, Saunders O et al (2010) A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol 28; 15s suppl:abstr e13065 Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P et al (2006) PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12:4080–4089 Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, Deutsch E (2007) Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 97:1664–1672 Lin ZZ, Hsu HC, Hsu CH, Yen PY, Huang CY, Huang YF, Chen TJ et al (2009) The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 50:518–527 Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 6:1–13 Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T et al (2009) In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Hematol 147:672–676 Lin R, Connolly PJ, Huang S, Wetter SK, Lu Y, Murray MV, Emanuel SL et al (2005) 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem 48:4208–4211 Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK et al (2005) The In vitro and In vivo effects of JNJ-7706621: A dual Inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 65:9038–9046 Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V et al (2007) Mechanism of action of the aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 6:3147–3157 Aurora kinase/VEGFR2 inhibitors (2010). http://www.telik.com/pdf/targets/Aurora.pdf. Accessed 6 May 2010 Rawson TE, Ruth M, Blackwood E, Burdick D, Corson L, Dotson J, Drummond J et al (2008) A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem 51:4465–4475 CHR-3520: Potent Aurora/multi-kinase inhibitor (2010). http://www.chromatherapeutics.com/Aurora-Kinase_backup.html. Accessed 26 April 2010 Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281–294 Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267–280 Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, Niquette A, Li J et al (2009) Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor AZD1152. Pharmacogenomics J 9:90–102 Seamon JA, Rugg CA, Emanuel S, Calcagno AM, Ambudkar SV, Middleton SA, Butler J, Borowski V, Greenberger LM (2006) Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther 5:2459–2467 Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S (2008) Molecular basis of drug of resistance in Aurora kinases. Chem Biol 15:552–562 Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B et al (1998) A homologue of drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065 Tatsuka M, Sato S, Kitajima S, Suto S, Kawai H, Miyauchi M, Ogawa I et al (2005) Overexpression of Aurora-A potentiates H-RAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 24:1122–1127 Ota Y, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M et al (2002) Increased mitotic phosphorylation of mitotic histone H3 attributable to AIM-1/Aurora B overexpression contributes to chromosome number instability. Cancer Res 62:5168–5177 Kanda A, Kawai H, Suto S, Kitajima S, Sato S, Takata T, Tatsuka M (2005) Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 24:7266–7272 Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H (2006) Comparing aurora A and aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther 5:2450–2458 Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS (2006) Validating aurora B as an anti-cancer drug target. J Cell Sci 119:3664–3675 Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170 Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E (2008) Enhancement of radiation response in p53-deficient cancer cells by Aurora-B kinase inhibitor AZD1152. Oncogene 22:3244–3255 Len SM, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10:825–841